COVID-19 Antibody Levels After Vaccines

Status Completed

Clinical Trial Summary

This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipuncture.

Clinical Trial Description

Based on data demonstrating that SARS-CoV-2 infections results in virus-specific nasal IgA levels even in patients with mild infections and no/low serum antibody titers, we hypothesize that COVID vaccinations result in robust nasal IgA levels. Since previous data indicate that SARS-CoV2 specific IgA were transiently present following community-acquired infections, we will follow vaccine-induced nasal IgA levels over time (6-12 months). Our specific aims are as following: Aim 1: Determine COVID vaccine specific immunoglobulin levels and immune mediator profiles in the nasal mucosa pre- and 14 days post second dose of COVID vaccine. Aim 2: Determine COVID specific immunoglobulin levels and immune mediator profiles at 3, 6, and 12 months following complete vaccination. ;

Study Design

Related Conditions & MeSH terms

Vaccine Preventable Disease

Clinical Trial Details

NCT number	NCT04944134
Study type	Observational
Source	University of North Carolina, Chapel Hill
Contact
Status	Completed
Phase
Start date	June 9, 2021
Completion date	April 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04542330` - Using BCG to Protect Senior Citizens During the COVID-19 Pandemic	Phase 3
Completed	`NCT04912661` - Iron and Vaccine Response	N/A
Completed	`NCT04904744` - Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination	N/A
Completed	`NCT05462249` - Impact of Catch-up HPV Vaccination
Recruiting	`NCT04899765` - Measles and BCG Vaccines for Mother and Child	Phase 4
Active, not recruiting	`NCT04817917` - Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province	Phase 4
Recruiting	`NCT04954092` - Study of Gam-COVID-Vac in Adolescents	Phase 2/Phase 3
Not yet recruiting	`NCT05140720` - Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age	N/A
Completed	`NCT04765839` - Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations	N/A
Active, not recruiting	`NCT04953130` - Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania	Phase 4
Withdrawn	`NCT04818736` - COVID-19 Vaccine For Indirect Protection	Phase 4